Compare · BSX vs ICCM
BSX vs ICCM
Side-by-side comparison of Boston Scientific Corporation (BSX) and IceCure Medical Ltd. (ICCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and ICCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 9249.5x ICCM ($7.8M).
- ICCM has been more active in the news (22 items in the past 4 weeks vs 11 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- Boston Scientific Corporation
- IceCure Medical Ltd.
- Price
- -
- -
- Market cap
- $72.26B
- $7.8M
- 1M return
- -
- -22.77%
- 1Y return
- -
- -92.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 22
- Recent ratings
- 25
- 2
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
- West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
- SEC Form EFFECT filed by IceCure Medical Ltd.
- SEC Form EFFECT filed by IceCure Medical Ltd.
- VP, Sales for North America Good Shad was granted 131,483 units of Ordinary Shares, increasing direct ownership by 2,521% to 136,698 units (SEC Form 4)
- SEC Form 3 filed by new insider Salton David
- VP, BD & Global Marketing Tel-Tzure Tlalit Bussi was granted 101,483 units of Ordinary Shares, increasing direct ownership by 2,016% to 106,518 units (SEC Form 4)
- VP, Human Resources Dotan Merav Nir was granted 73,890 units of Ordinary Shares, increasing direct ownership by 3,244% to 76,168 units (SEC Form 4)
- SEC Form 4 filed by Director Chan Vincent Chun Hung